Braun Stacey Associates Inc. Has $25.69 Million Stock Position in Neurocrine Biosciences, Inc. $NBIX

Braun Stacey Associates Inc. boosted its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 7.4% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 183,027 shares of the company’s stock after purchasing an additional 12,657 shares during the period. Braun Stacey Associates Inc. owned about 0.18% of Neurocrine Biosciences worth $25,693,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Geneos Wealth Management Inc. raised its stake in shares of Neurocrine Biosciences by 143.6% in the first quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock valued at $25,000 after acquiring an additional 135 shares during the last quarter. MAI Capital Management grew its position in Neurocrine Biosciences by 101.2% during the 2nd quarter. MAI Capital Management now owns 328 shares of the company’s stock worth $41,000 after acquiring an additional 165 shares during the last quarter. True Wealth Design LLC increased its holdings in Neurocrine Biosciences by 1,215.4% during the 2nd quarter. True Wealth Design LLC now owns 342 shares of the company’s stock valued at $43,000 after purchasing an additional 316 shares in the last quarter. Huntington National Bank raised its position in Neurocrine Biosciences by 26.4% in the 2nd quarter. Huntington National Bank now owns 604 shares of the company’s stock valued at $76,000 after purchasing an additional 126 shares during the last quarter. Finally, Elevation Point Wealth Partners LLC bought a new position in Neurocrine Biosciences in the 2nd quarter valued at $97,000. 92.59% of the stock is owned by institutional investors.

Neurocrine Biosciences Trading Up 0.6%

Neurocrine Biosciences stock opened at $141.83 on Friday. The company has a market cap of $14.14 billion, a PE ratio of 33.93, a PEG ratio of 0.93 and a beta of 0.28. Neurocrine Biosciences, Inc. has a 1 year low of $84.23 and a 1 year high of $160.18. The company’s 50-day moving average is $147.03 and its two-hundred day moving average is $139.17.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings results on Tuesday, October 28th. The company reported $2.17 EPS for the quarter, topping the consensus estimate of $1.58 by $0.59. The company had revenue of $794.90 million during the quarter, compared to analysts’ expectations of $746.61 million. Neurocrine Biosciences had a net margin of 15.95% and a return on equity of 15.82%. Neurocrine Biosciences’s revenue was up 27.8% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.81 EPS. Research analysts forecast that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current year.

Insider Activity

In other news, CEO Kyle Gano sold 300 shares of the firm’s stock in a transaction on Tuesday, November 4th. The stock was sold at an average price of $141.97, for a total value of $42,591.00. Following the transaction, the chief executive officer directly owned 140,407 shares in the company, valued at $19,933,581.79. This trade represents a 0.21% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director George J. Morrow sold 15,000 shares of Neurocrine Biosciences stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $143.37, for a total value of $2,150,550.00. Following the sale, the director directly owned 7,068 shares of the company’s stock, valued at approximately $1,013,339.16. This trade represents a 67.97% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 43,866 shares of company stock worth $6,570,237. Corporate insiders own 4.80% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. Wedbush restated an “outperform” rating on shares of Neurocrine Biosciences in a report on Monday, September 22nd. HC Wainwright upped their price target on shares of Neurocrine Biosciences from $168.00 to $198.00 and gave the stock a “buy” rating in a research report on Wednesday, December 17th. Citigroup increased their price objective on shares of Neurocrine Biosciences from $175.00 to $203.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Truist Financial reaffirmed a “buy” rating and issued a $172.00 target price (up from $165.00) on shares of Neurocrine Biosciences in a research note on Thursday, October 30th. Finally, Stifel Nicolaus upped their target price on shares of Neurocrine Biosciences from $183.00 to $188.00 and gave the stock a “buy” rating in a research report on Thursday, December 11th. Eighteen equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $175.25.

Neurocrine Biosciences Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.